Positron emission tomography for detection and staging of malignant lymphoma

FDG-Positron emission tomography (FDG-PET) is an imaging modality using the physiological tracer glucose [modified as 18-fluorine-2-fluorodeoxyglucose (FDG)], whose uptake and metabolism is increased in malignant cells. While exact tumor staging in lymphomatous diseases is the basis for choosing the...

Full description

Saved in:
Bibliographic Details
Published inRecent results in cancer research Vol. 156; p. 78
Main Authors Buchmann, I, Moog, F, Schirrmeister, H, Reske, S N
Format Journal Article
LanguageEnglish
Published Germany 2000
Subjects
Female
Fluorodeoxyglucose F18
Hodgkin Disease - diagnostic imaging
Hodgkin Disease - pathology
Humans
Lymphoma, Non-Hodgkin - diagnostic imaging
Lymphoma, Non-Hodgkin - pathology
Male
Neoplasm Staging
Tomography, Emission-Computed
Tomography, X-Ray Computed
Online AccessGet more information

Cover

More Information
Summary:FDG-Positron emission tomography (FDG-PET) is an imaging modality using the physiological tracer glucose [modified as 18-fluorine-2-fluorodeoxyglucose (FDG)], whose uptake and metabolism is increased in malignant cells. While exact tumor staging in lymphomatous diseases is the basis for choosing the appropriate treatment strategy, the detection of nodal and extranodal manifestations are a key prerequisite. This study demonstrates that FDG-PET is an efficient, non-invasive method for the staging of primary untreated Hodgkin's lymphoma (HD) and non-Hodgkin's lymphoma (NHL). Clinical PET scanning is very useful in staging lymphoma patients and is more accurate than computed tomography (CT) in detecting lesions.
ISSN:0080-0015
DOI:10.1007/978-3-642-57054-4_10